Bioxytran Inc (BIXT)

[Retire43]

Makes you want to buy more BIXT!

https://seekingalpha.com/article/4605537-pardes-bioscience-seeking-strategic-alternatives

[misiu143]

Good read..
https://www.zerohedge.com/news/2023-05-12/bidens-covid-over-proclamation-extinction-virus-or-lull-next-variant-0

[Retire43]

I, too, lost a lot money on the CYDY debacle! It was awful! And yes, the communications officer for Bioxytran was writing articles for them.

This is a Bioxytran and they have a number of drugs in the pipeline and a device that could literally change the world when it comes to viruses cancer, stroke, heart attack, TBI, sickle cell anemia and many other indications!

Look at the company, look at their products look at the CEO!

[theswordman]

Of course you did. Their VP of BS is the sheikh of nodderspeak. Pumped the indicted felon CEO of CYDY for years. He should be indicted for his pumper lies also. Good luck ms sooey

[Retire43]

I listened to all of BIXT talk.
It was very good.

Company pass, clinical trials, new clinical trials, coming, the need for funding

The company has some amazing drugs in the pipeline that need approval. I think they will change the world

Just like in 1928 with the discovery of an antibiotic penicillin. They didn’t know at the time but all types of infections it would cure

Just like today , this amazing antiviral we do not know how many different viruses it can cure! It might be all of them!

[BlazingStocks]

Did you listen to it all?

[Retire43]

Emerging Growth Conference was very good today.

[BlazingStocks]

Looking for $BIXT to tweet or PR about the conference...

About Bioxytran, Inc.

Bioxytran, Inc. is a clinical stage biotechnology company developing novel therapies targeting the treatment of significant unmet medical needs in virology, degenerative disease, and hypoxia. The leading drug candidate, ProLectin-M, is a new class of antiviral drug designed to antagonize galectins in Covid-19, influenza, and respiratory syncytial virus (RSV). ProLectin-I is also a galectin antagonist to target idiopathic pulmonary fibrosis and Long Covid. BXT-25 is an acellular oxygen carrier (AOC) designed to deliver oxygen to hypoxic tissues. Bioxytran’s other development programs are for ischemia of the heart and stroke treatment. More information can be found at www.bioxytraninc.com

[BlazingStocks]

Thank you for sharing that News link... Looking forward to hearing more from Bioxtran CCO Michael Sheikh about the medical and scientific communities’ reaction to the latest peer reviewed journal article at the Emerging Growth Conference on Wednesday.

$BIXT

[jedijazz]

$BIXT #MarketWatch "Bioxytran Interview at the Emerging Growth Conference" - Wednesday, May 3, 2023 12:35pm -1:05 pm EST -Medical/Scientific Community Reaction to Peer Reviewed Article https://www.marketwatch.com/press-release/bioxytran-interview-at-the-emerging-growth-conference-2023-05-01?reflink=mw_share_twitter $QH $ILAG

[QuicKtip]

$BIXT News! Bioxytran Interview at the Emerging Growth Conference
https://finance.yahoo.com/news/bioxytran-interview-emerging-growth-conference-120000517.html

[Retire43]

BIXT going to bff egg on twitter in less than one hour

[i_like_bb_stock]

agreed

[Retire43]

Yes.

This was the reason I first bought into this company!

Every EMT vehicle every ER in the world would have this sitting on the shelf ready

Heart attacks, stroke, traumatic brain injury, severe wounds of excess bleeding, sickle cell anemia

It may even be a cure for some forms of dementia .

[i_like_bb_stock]

news Bioxytran Tests Acellular Oxygen Carrier BXT-25 in Pre-Clinical Trials https://www.otcmarkets.com/stock/BIXT/news?id=397193

[i_like_bb_stock]

Agreed

[Retire43]

Yes. I’m hearing reports of a new variant attacking India! I hope they can catch this wave and complete clinical trials!

I want to see clinical trials on influenza as well!

[Retire43]

https://www.zerohedge.com/news/2023-04-12/white-house-blow-5-billion-project-nextgen

[i_like_bb_stock]

$BIXT almost ready to start clinical trials in India. With this large surge recruitment might be swifter than expected. Dose optimization.

— Mike Sheikh (@MikeSheikh2) April 13, 2023

[Retire43]

BIXT filed annual report!

[Retire43]

This is excellent news of a peer reviewed paper !

[Retire43]

So now Sir, what are your thoughts on BIXT?

There is a Reddit chat room form BIXT. It’s r/bixt! You can go put your two cents worth in there as well!

[ANTI-BAGHOLDER]

Some nice news out this morning

[jedijazz]

NEWS: Bioxytran Announces Positive Phase 2 Trial Results were Featured in “Vaccines” a Peer-Reviewed Journal
BIOXYTRAN, INC.
Wed, March 29, 2023 at 7:00 AM EDT
In this article: BIXT
+2.33%
Watchlist

BIOXYTRAN, INC.
Complete elimination of viral load in 100% of patients at day 7 vs 6% in placebo (p=.001)
Complete elimination of most symptoms by day 7
Galectin antagonist acts as an entry inhibitor for use in treatment of COVID-19

BOSTON, MASSACHUSETTS, March 29, 2023 (GLOBE NEWSWIRE) -- BIOXYTRAN, INC. (BIXT), (the “Company”), a clinical stage biotechnology company developing oral drugs to treat COVID-19 and other viral diseases, announced that the journal “Vaccines” released a peer-reviewed article, “An Oral Galectin Inhibitor in COVID-19 – A Phase 2 Randomized Controlled Trial”, which contains top-line safety and efficacy results of the Company’s randomized, placebo-controlled Phase 2 clinical trial in 34 patients with mild-to-moderate COVID-19. During the 7 days of treatment, an orally administered Galectin Antagonist in the form of a chewable tablet was administered. The endpoint was a statistically significant reduction in viral load measured by the number of patients reaching a below threshold PCR value (Ct value ≥ 29) by day 7. Additionally, most of the symptoms completely disappeared in the group receiving the drug whereas the placebo group had 41.18% of patients that continued to experience chills, 29.41% that had a feverish sensation, and 35.29% that had a cough on day 7. The trial met its endpoint with a 100% response rate by day 7 versus 6% in placebo, which was statistically significant (p-value =.001).

Our analysis also revealed an 82% responders rate by day 3, which was statistically significant (p-value = .001). There were no drug-related serious adverse events (SAE’s) in the patient population or viral rebounds by day 14. The positive data from this clinical trial provided the rationale of dosing and protocol design for study in an upcoming phase 2/3 registrational trial.

The full text of the journal article is located at the following link.
https://www.mdpi.com/2076-393X/11/4/731

“After considering all the clinical data and tests it is clear that ProLectin-M could play a major role in treating future pandemics. The drug dramatically reduced the viral load which in turn shuts down the transmission of the virus. Recent analysis reveals that reducing the number of days of infectivity can have a dramatic impact on the number of overall infections, hospitalizations, and economic burden” said Dr. Alben Sigamani, a member of Bioxytran’s Medical Advisory Board. Dr. Sigamani continued by stating “The key to stopping this cycle of immune evasion is to quickly treat the infected and provide prophylaxis to those exposed. The trial results demonstrate we may be able to do both. This is why we are looking forward to starting our dosage optimization study which will inform our Phase 3 study and future trial designs.”

“Existing therapies target viral replication which battles on the inside of the cell interfering with replication, our Galectin Antagonist helps keep the fight outside the cell interfering with cellular entry. This novel Mechanism of Action in battling viruses may require little assistance from the immune system, which typically requires a lead time to mount a response. With the creation of this molecule, we contribute to the science of Glycovirology, which is the study of carbohydrates and viruses.”

“This is truly a groundbreaking study that demonstrates the proof of concept of a carbohydrate molecule capable to influence and block infection by a virus.” said Dr. Hana Chen-Walden, Medical Director of Bioxytran. “In the past, before the COVID-19 epidemic, vaccines were used to stop the viral spread and thus eradicate the disease. This ideal was not supported by the new COVID19 vaccines, in face of the continuation of the spread of the virus with the appearance of new mutant virus variants which were not controlled by the vaccine. It became evident that other tools will have to be used against the spread of disease contributing to its prophylaxis”.

“We intend to explore not only COVID-19, but also other viruses and indications. The underlying concept of Glycovirology, is that viral and human membranes are glycosylated. The Galectin Fold or the protein receptors called Lectins which recognize only carbohydrates chemical structures are unique to each virus. Our challenge will be to identify the unique galectins structure on each virus and then the specific complex carbohydrate chemical structures that will bind to the galectin fold to achieve complete binding and inhibition of viral entry. Recent journal articles have demonstrated the utility of using high power resolution of NMR mathematical calculations as drug design tool to quickly assess the binding affinity theoretically. It is for these reasons we believe we have a vast and major novel platform technology that could effectively treat other serious viral diseases.”

About Bioxytran, Inc.

Bioxytran, Inc. is a clinical stage biotechnology company developing novel therapies targeting the treatment of significant unmet medical needs in virology, degenerative disease, and hypoxia. The leading drug candidate, Prolectin-M, is a new class of antiviral drug designed to antagonize galectins implicated in inflammatory, fibrotic, and malignant diseases. Bioxytran’s other development programs are for pulmonary fibrosis and stroke treatment. More information can be found at www.bioxytraninc.com

Investor Relations
Michael Sheikh
509-991-0245
[e-mail]

Forward-Looking Statements

This press release includes forward-looking statements as defined under federal law, including those related to the performance of technology described in this press release. These forward-looking statements are generally identified by the words “believe,” “expect,” “anticipate,” “estimate,” “intend,” “plan,” and similar expressions, although not all forward-looking statements contain these identifying words. Such statements are subject to significant risks, assumptions and uncertainties. Known material factors that could cause Bioxytran’s actual results to differ materially from the results contemplated by such forward-looking statements are described in the forward-looking statements and risk factors in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2021 and those risk factors set forth from time-to-time in other filings with the Securities and Exchange Commission. Bioxytran undertakes no obligation to correct or update any forward-looking statement, whether as a result of new information, future events, or otherwise, except to the extent required under federal securities laws.

[Retire43]

How can you possibly say that when 88% had no symptoms in three days and 100% at seven days and there were no reoccurrences 14 days out! F?

[Retire43]

https://microcapdaily.com/bioxytran-otcmkts-bixt-peer-review-published-showing-functional-cure-for-covid-19/

[Zardiw]

No Problem......just calling it like I see it.......and this thing of $BIXT isn't effective according to the results they posted.............Z

[Zardiw]

Not what the charts showed......

Z

[Retire43]

What is your problem?

Do you not remember that for 26 months, we were not trading? Because of the Weaponized government was protecting their Covid vaccine

[Retire43]

Are you drunk or on drugs?

88% were symptom-free in three days! It was 100% effective.

[Retire43]

Activity in Influenza and Respiratory Syncytial Virus highlights the broad- spectrum antiviral potential of ProLectin-M

BOSTON, MASSACHUSETTS, Feb. 28, 2023 (GLOBE NEWSWIRE) -- BIOXYTRAN, INC. (OTCQB: BIXT) (the “Company”), a clinical stage biotechnology company developing oral and intravenous drugs to treat COVID-19, other viral diseases, and fibrosis announced today that in vitro testing at the Foundation for Neglected Disease Research (FNDR) in Bangalore India, showed that leading drug candidate ProLectin-M (PL-M) showed a significant reduction of viral load in influenza (H1N1) and in human Respiratory Syncytial Virus (RSV). The newest in vitro results, completed in early February 2023, are similar in nature to the SARS-CoV-2 test results that ultimately led to the successful completion of 2 clinical trials. The positive data and the non-toxic nature of the molecule justifies an IND filing to proceed to phase 2 human clinical trials.
These in vitro test results add to the body of evidence that PL-M has the potential to be a broad-spectrum antiviral useful in the treatment of Upper Respiratory Infections (“URI”) and as a potential treatment of populations infected by a “tripledemic” recently warned of by public health officials: that is peak infections, at the same time, of RSV, Influenza, and COVID-19. In December 2022 a wave of COVID-19, RSV, and Influenza infections hit all at once putting pressure on the hospital systems by maxing out the number of beds available. This pressure on the hospital systems had no relieve valve because there are no triage like treatments for standard risk patients.
Influenza has been infecting people worldwide since the 1500’s and the only way to control influenza is through the use of personal protective measures and frequent handwashing. There are a number of antiviral treatment options like oseltamivir phosphate (Tamiflu®) which was the positive control in our study, but these antivirals are designed to inhibit replication and must be taken within two days of symptoms. PL-M has a different mechanism of action as an entry inhibitor, and is designed to stop infectivity and spread of the disease throughout the body.
RSV is a highly contagious virus that primarily effects babies and older adults with underlying medical conditions and can lead to serious infections, including bronchiolitis, and pneumonia. There are over 57,000 hospitalizations, 500,000 emergency room visits and 1.5 million outpatient clinic visits among children less than 5 years of age that contract RSV. In adults there are 177,00 hospitalizations and 14,000 deaths annually.1 There are no known treatments except the management of the symptoms. Drug developers are working on vaccines and antiviral treatments.
With this excellent in vitro data in hand from influenza and RSV, the Company anticipates it will add additional treatment arms to its COVID-19 studies.
About ProLectin-M
ProLectin-M is an oral galectin antagonist that prevents the entry of the SARS-CoV-2 virus into human cells. In recent clinical trials the drug achieved a 100% responders rate of negative PCR tests by day 7. In 3 days, the drug achieved an 88% responders rate of negative PCR tests. The treated population experienced no viral rebounds during the 14-day observation period. The company is preparing for a phase 3 clinical trial in order to seek regulatory approval.
About Bioxytran, Inc.
Bioxytran, Inc. is a clinical stage biotechnology company developing novel therapies targeting the treatment of significant unmet medical needs in virology, degenerative disease, and hypoxia. The leading drug candidates, ProLectin-M (“PLM”) and ProLectin-I (“PLI”), are a new class of antiviral drugs designed to antagonize galectins implicated in viral, inflammatory, fibrotic, and malignant diseases. Bioxytran’s other development programs are for pulmonary fibrosis and stroke treatment. More information can be found at www.bioxytraninc.com
Investor Relations

Michael Sheikh

509-991-0245

[e-mail]
Forward-Looking Statements
This press release includes forward-looking statements as defined under federal law, including those related to the performance of technology described in this press release. These forward-looking statements are generally identified by the words “believe,” “expect,” “anticipate,” “estimate,” “intend,” “plan,” and similar expressions, although not all forward-looking statements contain these identifying words. Such statements are subject to significant risks, assumptions and uncertainties. Known material factors that could cause Bioxytran’s actual results to differ materially from the results contemplated by such forward-looking statements are described in the forward-looking statements and risk factors in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2021 and those risk factors set forth from time-to-time in other filings with the Securities and Exchange Commission. Bioxytran undertakes no obligation to correct or update any forward-looking statement, whether as a result of new information, future events, or otherwise, except to the extent required under federal securities laws.
1 CDC – National Notifiable Disease Surveillance System (NNDSS)



Primary Logo

Source: BIOXYTRAN, INC.

[Zardiw]

On 11-16-22, $BIXT added 5M to the Float (+38%!). On 1-24-23 they added another 1M to the Float. That's 6M Total.

Here's the Trading Volume since 11-17-22: 5,484,289.

SO, looks like there's another 500M shares to dilute until they're done selling them........

Trading Data since 11-17-22:
-25%
Dollars: $2,770,572
Volume: 5,484,289

1-24-23 - FL Inc - New: 19, Old: 18, Chg: +1, +6% **
12-12-22 - Address Chg - New: 75, Second Avenue, Needham, MA -- Old: 75, Needham, MA **
11-16-22 - FL Inc - New: 18, Old: 13, Chg: +5, +38% **
8K: 11-14-22 - material definitive agreement **
Tier: 9-30-22 - New: OTCQB - Old: Current **

Z

[Zardiw]

You know what's worse than somebody saying No when you ask them to do something?

Them saying yes and then stringing you along and not doing it......lolol

That's sheick for you........fwiw

Z

[Zardiw]

How many years has it been now. I think we've all been scammed by $BIXT........snake oil.......


Z

[Zardiw]

Seems like that clinical trial didn't work....some charts show that this $BIXT drug seems to actually make it worse.......

Z

[Zardiw]

Yawwwwnnnnnn.....................

Z

[Zardiw]

I think that actually makes it worse.........lol.........

Z

[Retire43]

Amazing news on BIXT!

https://www.zerohedge.com/news/2023-03-07/sick-jabs-and-rebounds-breakthrough-antiviral-flushes-out-multiple-viruses

[Retire43]

https://www.mdpi.com/2076-393X/11/4/731

[Retire43]

A promising new drug being trialed for Covid:

'Most of the symptoms disappeared completely after receiving PL-M treatment for 7 days in more patients compared to the placebo group. Conclusion: PL-M is safe and effective for clinical..https://t.co/EmrUu0k03f

— Chris Turnbull (@EnemyInAState) March 26, 2023

[tradernewstip]

Watch About BioxyTran Inc, Emerging Growth Highlights Reel $BIXT

[tradernewstip]

$BIXT Has big news update coming.. stay tuned!!

[Retire43]

It’s going to take time and money to get through clinical trials! More people see and hear of this, chances are it attracts some deep pocket investors!

[theswordman]

The importance is in the cure--not the pump

Lot of cred lost when u go from CYDY support/CEO Pourhassan then follow sheikh over here because he works as vp of BIXT. Leaving out that CEO pourhassan is indicted by DOJ AND SEC because of fraud pumper articles and posters--sheikh et al

If this drug works--no need to pump for you penny flippers to make money

Let the real clinical trial do the pump--not the eco and bb and 43s

[Retire43]

I think investors like ourselves should be posting this everywhere we can to get more eyes on this company increasing its exposure and presence to the general public!

Can you imagine the enormous importance it is to prove BIXT can cure a virus?

[Zardiw]

Nice article...............Z

[$theDDmessiah]

This is looking great

[Retire43]

https://insiderfinancial.com/bixt-spikes-on-delayed-reaction-to-the-most-powerful-drug-since-penicillin/184050/

[SHEEPWOLF]

$BIXT 32X AVERAGE VOLUME....people are catching on to this one
Huge news
RW for S-1
low float
huge short position
BIG MOVE AHEAD

[Ecomike]

IMO, $BIXT will be the next Moderna, not vaccines like Moderna, but a whole new class of Antivials, starting with Covid19.

And it is no toxic, no negative side effects. Shocker

Repeat covid19 infections, Long Haul Covid caused by Covid19 spikes make by the immune system over reacting to the mRNA vaccines, or frequent re-exposure to others with the highly contagious Omicron strains, have huge potential as well for the $BIXT product.

There is another I think, with a solid opp for Immune system caused Long Haul Covid19 caused by Micro blood clots (recent research) that just US FDA approval for end points to change of the nearly finished Covid19 trial, that is following a path I suggested last summer, of adding Long haul Covid to the trail data.
It is Rvvtf

I own shares in both, and will be accumulating more shares of both this year.
I do not see them as competitors. Long story.....

These are the only two I think have a real shot at game changer results, and mega Billion dollar buy outs.